title: [Inhibitory effect of norcantharidin combined with evodiamine on the growth of human hepatic carcinoma cell line HepG2 in vitro].
abstract: OBJECTIVE
  To investigate the combined effect of evodiamine (EVO) and norcantharidin (NCTD) on HepG2 cells.
  
  
  METHODS
  HepG2 cells were treated with EVO or/and NCTD at different concentrations in vitro, with blank culture medium as the negative control. The inhibitory effect of EVO or/and NCTD was determined by MTT assay. Cell cycle and cell apoptosis were assessed by flow cytometry (FCM) combined with PI staining and annexin V-FITC/PI, respectively. The expressions of Bax and Bcl-2 were examined by Western blotting. RESULTS MTT assay showed that NCTD and EVO had restraining effect on the growth of HepG2 cells. The combination of NCTD and EVO had significant synergistic inhibition effect (CI<1). The arrest rate of G2/M phase was (36.13±1.63)% in the EVO induced group and (10.67±0.89)% in the NCTD induced group, and the combination of EVO and NCTD up-regulated the rate to (73.42±1.92)% (P<0.05). In addition, the apoptosis rate of HepG2 cells treated by two-drug combination increased significantly from (15.78 ± 3.08)% in the EVO group and (11.47 ± 1.60)% in the NCTD group to (21.86±2.70)% in the EVO combined with NCTD group (P<0.05). Western blotting demonstrated that the expression level of Bax protein went up significantly (P<0.05), meanwhile Bcl-2 protein dropped significantly (P<0.05) in the combined induced group.
  
  
  CONCLUSIONS
  EVO combined with NCTD showed synergetic effect on anti-proliferation and pro-apoptosis in HepG2 cells.
authors.affiliation: Medicine Engineering Research Center, Chongqing Medical University, Chongqing Medical University, Chongqing 400016, China.
authors.forename: Yumin
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Medicine Engineering Research Center, Chongqing Medical University, Chongqing Medical University, Chongqing 400016, China.
authors.forename: Jingqing
authors.initials: J
authors.lastname: Zahng
authors.affiliation: Laboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University, Chongqing 400016, China.
authors.forename: Zhimei
authors.initials: Z
authors.lastname: You
authors.affiliation: Medicine Engineering Research Center, Chongqing Medical University, Chongqing Medical University, Chongqing 400016, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Liao
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D015153:Blotting, Western; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005434:Flow Cytometry; D059565:G2 Phase Cell Cycle Checkpoints / Q000187:drug effects; D056945:Hep G2 Cells; D018197:Hepatoblastoma / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism / Q000473:pathology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D011799:Quinazolines / Q000494:pharmacology*; D051028:bcl-2-Associated X Protein / Q000378:metabolism
chemical_list: D019086:Bridged Bicyclo Compounds, Heterocyclic; D019253:Proto-Oncogene Proteins c-bcl-2; D011799:Quinazolines; D051028:bcl-2-Associated X Protein; C069741:norcantharidin; C049639:evodiamine